Charles Silberstein, Chief Financial Officer of NovaBridge Biosciences, filed an initial statement of beneficial ownership on November 2, 2026, reporting no securities beneficially owned.
Key Highlights
- Reporting person: Charles Silberstein, identified as Chief Financial Officer of NovaBridge Biosciences.
- Event date: The date of event requiring the statement is listed as 11/02/2026.
- No securities held: Both Table I (non-derivative securities) and Table II (derivative securities) are blank; the filing states "No securities are beneficially owned."
- Filing type: This is an initial statement, not an amendment.
- Issuer: NovaBridge Biosciences, trading under the ticker NBP, listed on NASDAQ:NBP.
Silberstein Reports Zero Beneficial Ownership Upon Joining NovaBridge Biosciences
Charles Silberstein submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - with the U.S. Securities and Exchange Commission on November 2, 2026, in connection with his role as Chief Financial Officer at NovaBridge Biosciences (NASDAQ:NBP). The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and certain shareholders to disclose their initial beneficial ownership of issuer securities upon becoming an insider.
According to the filing, Silberstein does not beneficially own any non-derivative or derivative securities of NovaBridge Biosciences. Table I, covering direct and indirect holdings of non-derivative securities, contains no entries. Table II, covering derivative securities such as options, warrants, or convertible instruments, is likewise empty. The filing explicitly states "No securities are beneficially owned." The form was filed by one reporting person and is not an amendment to a prior filing.
Silberstein's address of record is listed as c/o NovaBridge Biosciences, 2440 Research Boulevard, Suite 400, Rockville, Maryland 20850. The filing was signed by Charles Silberstein and dated November 2, 2026.
What Was Disclosed
Charles Silberstein filed an initial beneficial ownership statement as CFO of NovaBridge Biosciences, dated November 2, 2026, disclosing no direct or indirect holdings of any non-derivative or derivative securities of the issuer.




Please wait processing your request...